198 related articles for article (PubMed ID: 15389347)
1. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
Szucs TD; Sandoz MS; Keusch GW
Swiss Med Wkly; 2004 Aug; 134(31-32):440-7. PubMed ID: 15389347
[TBL] [Abstract][Full Text] [Related]
2. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
[TBL] [Abstract][Full Text] [Related]
3. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B
Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859
[TBL] [Abstract][Full Text] [Related]
4. Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
Seng WK; Hwang SJ; Han DC; Teong CC; Chan J; Burke TA; Carides GW; Choi YJ
Nephrology (Carlton); 2005 Oct; 10(5):520-4. PubMed ID: 16221106
[TBL] [Abstract][Full Text] [Related]
5. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
[TBL] [Abstract][Full Text] [Related]
6. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
Herman WH; Shahinfar S; Carides GW; Dasbach EJ; Gerth WC; Alexander CM; Cook JR; Keane WF; Brenner BM
Diabetes Care; 2003 Mar; 26(3):683-7. PubMed ID: 12610022
[TBL] [Abstract][Full Text] [Related]
7. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
de Portu S; Citarella A; Cammarota S; Menditto E; Mantovani LG
Clin Exp Hypertens; 2011; 33(3):174-8. PubMed ID: 21466388
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective.
Stafylas PC; Sarafidis PA; Lasaridis AN; Tsakni E; Niakas DA; Dombros NV; Grekas DM; Bakris GL
J Nephrol; 2007; 20(6):703-15. PubMed ID: 18046673
[TBL] [Abstract][Full Text] [Related]
9. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Alexander CM; Lyle PA; Keane WF; Carides GW; Zhang Z; Shahinfar S
Kidney Int Suppl; 2004 Nov; (92):S115-7. PubMed ID: 15485403
[TBL] [Abstract][Full Text] [Related]
10. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
Carides GW; Shahinfar S; Dasbach EJ; Keane WF; Gerth WC; Alexander CM; Herman WH; Brenner BM;
Pharmacoeconomics; 2006; 24(6):549-58. PubMed ID: 16761903
[TBL] [Abstract][Full Text] [Related]
11. Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom.
Vora J; Carides G; Robinson P
Curr Ther Res Clin Exp; 2005 Nov; 66(6):475-85. PubMed ID: 24678070
[TBL] [Abstract][Full Text] [Related]
12. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France.
Souchet T; Durand Zaleski I; Hannedouche T; Rodier M; Gaugris S; Passa P;
Diabetes Metab; 2003 Feb; 29(1):29-35. PubMed ID: 12629445
[TBL] [Abstract][Full Text] [Related]
13. [Economic impact of Losartan use in type 2 diabetic patients with nephropathy].
González F F; Fuentes C V; Castro H C; Santelices L JP; Lorca H E
Rev Med Chil; 2009 May; 137(5):634-40. PubMed ID: 19701552
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001.
Sandoz MS; Ess SM; Keusch GW; Schwenkglenks M; Szucs TD
Swiss Med Wkly; 2004 Aug; 134(31-32):448-58. PubMed ID: 15389348
[TBL] [Abstract][Full Text] [Related]
15. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Ruilope LM; Segura J
Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
[TBL] [Abstract][Full Text] [Related]
16. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
[TBL] [Abstract][Full Text] [Related]
17. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B; Gleim G; Panish J
Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
[TBL] [Abstract][Full Text] [Related]
18. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy.
Ravera M; Re M; Vettoretti S
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S44-8. PubMed ID: 16565246
[TBL] [Abstract][Full Text] [Related]
20. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
Rodby RA; Firth LM; Lewis EJ
Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
